Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.

The American journal of medicine·2013

Same author

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

The American journal of cardiology·2013

Same author

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation·2013

Same author

Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Clinical cardiology·2013

Same author

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.

Circulation·2013

Same author

Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Journal of the American College of Cardiology·2013

Same journal

Surgical Fixation Versus Cast Immobilization for Adults With Bicortical Scaphoid Fractures: A Target Trial Emulation of the SWIFFT Trial.

The Journal of the American Academy of Orthopaedic Surgeons·2026

Same journal

Dementia as a Marker of Poor Outcome After Hip Hemiarthroplasty.

The Journal of the American Academy of Orthopaedic Surgeons·2026

Same journal

Fix or Replace: Evidence for Treatment Options in the Management of Femoral Neck Fractures.

The Journal of the American Academy of Orthopaedic Surgeons·2026

Same journal

Epidemiology, Treatment Patterns, and Comorbidities of Trigger Finger: A Contemporary Population-Based Analysis.

The Journal of the American Academy of Orthopaedic Surgeons·2026

Same journal

Posterior Approaches to Pilon Fractures: Considerations, Indications, and Outcomes.

The Journal of the American Academy of Orthopaedic Surgeons·2026

Same journal

Effect of Season on Patient-reported Outcomes and Discharge Disposition in Total Hip and Knee Arthroplasty.

The Journal of the American Academy of Orthopaedic Surgeons·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Soft-tissue sarcoma.

Nathan F Gilbert¹, Christopher P Cannon, Patrick P Lin

¹Department of Orthopaedic Oncology,The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1420, USA.

The Journal of the American Academy of Orthopaedic Surgeons

|January 13, 2009

Summary

This summary is machine-generated.

Soft-tissue sarcomas, rare cancers originating from connective tissues, often present as painless masses. Treatment focuses on limb-sparing surgery, with radiation for difficult cases, while chemotherapy remains controversial.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

Orthopaedic Surgery
Surgical Oncology
Medical Oncology

Background:

Soft-tissue sarcomas are rare malignancies originating from mesodermal tissues.
Commonly affect extremities, trunk, retroperitoneum, and head/neck, with extremity and pelvic sarcomas being most relevant to orthopaedic surgeons.
Patients typically present with a painless, enlarging mass.

Purpose of the Study:

To review the diagnosis and management of soft-tissue sarcomas, particularly those relevant to orthopaedic practice.
To highlight the importance of advanced imaging and biopsy at specialized centers.
To discuss current treatment strategies and their controversies.

Main Methods:

Review of diagnostic modalities including advanced imaging and biopsy.
Discussion of prognostic factors: size, location, grade, histology, stage, patient age, and comorbidities.
Analysis of treatment options: surgical resection, radiation therapy, and chemotherapy.

Main Results:

Diagnosis is typically confirmed via advanced imaging and biopsy at tertiary referral centers.
Limb-sparing surgical resection is the primary treatment modality.
Radiation therapy is utilized for unresectable tumors or as neoadjuvant/adjuvant therapy.
The role of chemotherapy is debated, with no established standard protocol.

Conclusions:

Management of soft-tissue sarcomas is multifactorial, influenced by tumor characteristics and patient factors.
Limb-sparing surgery and radiation are established treatment components.
Further research is needed to clarify the role of chemotherapy in soft-tissue sarcoma treatment.